Edition:
United States

Cambrex Corp (CBM)

CBM on New York Consolidated

44.02USD
26 Aug 2016
Change (% chg)

$0.15 (+0.34%)
Prev Close
$43.87
Open
$43.97
Day's High
$44.49
Day's Low
$43.51
Volume
233,793
Avg. Vol
389,683
52-wk High
$59.41
52-wk Low
$29.50

Summary

Name Age Since Current Position

Shlomo Yanai

63 2014 Non-Executive Chairman of the Board

Steven Klosk

58 2008 President, Chief Executive Officer, Director

Gregory Sargen

50 2011 Chief Financial Officer, Executive Vice President

Shawn Cavanagh

49 2011 Chief Operating Officer, Executive Vice President

Samantha Hanley

38 2013 Vice President, General Counsel, Secretary

James Farrell

49 2007 Vice President and Corporate Controller

Aldo Magnini

61 2014 Managing Director of Cambrex Profarmaco Milano

Claes Glassell

65 2016 Director

Louis Grabowsky

64 2015 Director

Rosina Dixon

72 1995 Independent Director

Kathryn Harrigan

64 1994 Independent Director

Leon Hendrix

73 1995 Independent Director

Ilan Kaufthal

67 1983 Independent Director

Peter Tombros

72 2002 Independent Director

Stephanie LaFiura

Investors Relations Associate

Biographies

Name Description

Shlomo Yanai

Mr. Shlomo Yanai is Non-Executive Chairman of the Board of Cambrex Corp. Mr. Yanai served from 2007 until mid-2012 as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a global generic pharmaceutical leader and one of the top 15 global pharmaceutical companies in the world. From 2003 to 2006, Mr. Yanai was the President and Chief Executive Officer of Makhteshim Agan Industries, a leading global agro-chemicals company. Mr. Yanai also served as a member of the Board of Directors of the Bank Leumi Le-Israel, Israel’s second largest bank, LycoRed Natural Products Industries and I.T.L. Optronics Ltd. Until his retirement from the Israeli Army in 2001 at the rank of Major General, Mr. Yanai was the head of the Strategy Planning Branch of General Headquarters of the Israel Defense Forces.

Steven Klosk

Mr. Steven M. Klosk is President, Chief Executive Officer, Director of Cambrex Corporation since 2008. Mr. Klosk joined Cambrex in October 1992 and has served as President and Chief Executive Officer since May 2008. He also became a member of the Board of Directors in May 2008. Mr. Klosk joined the Company as Vice President, Administration. He was appointed Executive Vice President, Administration in October 1996 and was promoted to the position of Executive Vice President, Administration and Chief Operating Officer for the Cambrex Pharma and Biopharmaceutical Business Unit in October 2003. In January 2005, Mr. Klosk assumed direct responsibility for the leadership of the Biopharmaceutical Business Unit as Chief Operating Officer. In August 2006, Mr. Klosk assumed the responsibility of the Pharma business as Executive Vice President and Chief Operating Officer – Biopharma & Pharma and in February 2007 was appointed to Executive Vice President, Chief Operating Officer and President, Pharmaceutical Products and Services. From 1988 until he joined Cambrex, Mr. Klosk was Vice President, Administration and Corporate Secretary for The Genlyte Group, Inc. From 1985 to 1988, he was Vice President, Administration for Lightolier, Inc., a subsidiary of The Genlyte Group, Inc. Mr. Klosk currently serves on the Board of Directors of Caladrius Biosciences, Inc., a publicly traded cell therapy company.

Gregory Sargen

Mr. Gregory P. Sargen is Chief Financial Officer, Executive Vice President of the Company since 2011. Mr. Sargen joined Cambrex in February 2003 and has served as Vice President and Chief Financial Officer since February 2007 and Executive Vice President and Chief Financial Officer since January 2011. Mr. Sargen previously held the position of Vice President, Finance. Previously, he was with Exp@nets, Inc. from 1999 through 2002, serving in the roles of Executive Vice President, Finance/Chief Financial Officer and Vice President/Corporate Controller. From 1996 to 1998, he was with Fisher Scientific International’s Chemical Manufacturing Division, serving in the roles of Vice President, Finance and Controller. Mr. Sargen has also held various positions in finance, accounting and audit with Merck & Company, Inc., Heat and Control, Inc., and Deloitte & Touche.

Shawn Cavanagh

Mr. Shawn P. Cavanagh is Chief Operating Officer, Executive Vice President of Cambrex Corporation since 2011. Mr. Cavanagh joined Cambrex in January 2011 and has served as Executive Vice President and Chief Operating Officer since he joined Cambrex. From 2007 to 2009 Mr. Cavanagh was employed with Lonza, which purchased Cambrex Bioproducts, most recently as President of Lonza Bioscience. From 1999 to 2007, Mr. Cavanagh worked for Cambrex Bioproducts. While at Cambrex Bioproducts, Mr. Cavanaugh held several positions of increasing responsibility including President of Cambrex Bioproducts. Prior to joining Cambrex Bioproducts, Mr. Cavanagh held various management and engineering positions with FMC Corporation.

Samantha Hanley

Ms. Samantha M. Hanley is Vice President, General Counsel, Secretary of the Company since 2013. Ms. Hanley joined Cambrex in April 2009 and has served as Assistant General Counsel and Assistant Secretary since January 2013, and as Vice President, General Counsel and Secretary since February 2015. Ms. Hanley previously held the position of Senior Intellectual Property/Corporate Counsel and Assistant Secretary. Prior to joining Cambrex, Ms. Hanley worked at Alpharma Pharmaceuticals as Director of Intellectual Property and was an Associate with Lerner, David, Littenberg, Krumholtz & Mentlik, LLP, an intellectual property law firm.

James Farrell

Mr. James G. Farrell is Vice President and Corporate Controller of the Company since 2007. Mr. Farrell joined Cambrex in September 2005 as Corporate Controller. He has served as Vice President and Corporate Controller since July 2007, except for a portion of 2008 when Mr. Farrell was employed by PDI, Inc. as Vice President and Corporate Controller/Interim Chief Financial Officer. From 1994 until 2005, he was with Ingersoll-Rand Company, most recently as Director, Accounting Policy, Procedures and External Reporting. Mr. Farrell was with Ernst & Young from 1988 to 1994, most recently as Audit Manager.

Aldo Magnini

Dr. Aldo G. Magnini is Managing Director of Cambrex Profarmaco Milano a subsidary of Cambrex Corp. Dr. Magnini joined Cambrex Profarmaco Milano S.r.l. (“CPM”) in 1996 as Commercial Director, Marketing and Sales; in 2005, he became Managing Director and in January 2014 has assumed full responsibility of CPM. Prior to joining CPM, Dr. Magnini held various senior management roles in other pharmaceutical companies and from 2003 to 2004 served as Managing Director of Clariant Pharma, an Italian API manufacturer.

Claes Glassell

Mr. Claes Glassell is Director of the Company. Prior to joining Cambrex as a board member, from 2011 through 2015, Mr. Glassell was Chief Executive Officer of CMC Biologics, a contract manufacturing organization with 500 employees globally. From 2004 through 2011, Mr. Glassell was Chief Executive Officer of Cerus Corp., a publicly held medical device company. Before joining Cerus Corp., Mr. Glassell spent over eight years at Cambrex Corporation as President and Chief Operating Officer. From 1989 through 1994, Mr. Glassell was President and CEO of Nobel Chemicals and Senior Vice President of Nobel Industries. He has a Master’s degree in Chemical Engineering from Chalmers University of Technology. Mr. Glassell has served on the boards of several public and private companies, including Vitrolife AB, Cellartis AB, Nobel Chemicals, Berol Nobel, Cambrex, Cerus, CMC Biologics, Swedish American Chamber of Commerce, and Swedish Chemical Industry Association.

Louis Grabowsky

Mr. Louis J. Grabowsk is Director of Cambrex Corporation. Mr. Grabowsky is a co-founder and principal of Juniper Capital Management, a financial sponsor that provides capital to high-growth potential but under-resourced entrepreneurial companies based in the United States. Prior to founding Juniper Capital Management, Mr. Grabowsky was a partner with Grant Thornton LLP. Before his retirement from Grant Thornton in 2014, Mr. Grabowsky served as the Chief Operating Officer of the U.S. firm from 2009 to 2013. In that role, Mr. Grabowsky oversaw the execution of the firm’s strategy through each of the businesses and geographies. The U.S. operations of Grant Thornton included over 6,500 personnel with net revenues approximating $1.3 billion. Before becoming Chief Operating Officer, Mr. Grabowsky held several leadership roles at Grant Thornton. From 2006 until 2009, he served as Managing Partner for the Central Region and was responsible for the day-to-day operations of eight offices across four states. From 2003 to 2006, Mr. Grabowsky led the Dallas, Texas office and was also a member of the firm’s Partnership Board. Prior to joining Grant Thornton, Mr. Grabowsky served for a total of 27 years in various positions with Arthur Andersen LLP, including 17 years as a partner. Currently, Mr. Grabowsky is a member of the board of directors of Griffon Corporation (NYSE: GFF), ClubCorp Holdings, Inc. (NYSE: MYCC) and several civic and charitable organizations.

Rosina Dixon

Dr. Rosina B. Dixon, M.D., is Independent Director of Cambrex Corporation. She is a Chairperson of the Compensation Committee and Member of the Regulatory Affairs Committee of the Board. Dr. Dixon has been Medical Director, Advance Biofactures Corp., a pharmaceuticals company in Lynbrook, NY, since January 2012. Prior to that she was Senior Director, Global Pharmacovigilance and Epidemiology at Sanofi-Aventis, a global biopharmaceuticals company located in Bridgewater, NJ from 2006 to 2011. From May 1986 to September 2006 she was a consultant to the pharmaceutical industry. Dr. Dixon previously served as Vice President and Secretary of Medical Market Specialties Incorporated, as well as a member of its Board of Directors. She was also previously Medical Director, Schering Laboratories, Schering-Plough Corporation. Prior to that, Dr. Dixon was Executive Director Biodevelopment, Pharmaceuticals Division, CIBA-GEIGY Corporation. Dr. Dixon had been a member of the Board of Directors of Church & Dwight Co., Inc. since 1979 until her retirement in May 2014.

Kathryn Harrigan

Dr. Kathryn Rudie Harrigan is Independent Director of Cambrex Corporation.She is a Member of the Audit and Regulatory Affairs Committees of the Board. In 1993, Dr. Harrigan became the first Henry R. Kravis Professor of Business Leadership at Columbia University Business School. Dr. Harrigan was previously Professor, Management Division of the Columbia University Business School and Academic Director of the Jerome A. Chazen Institute for International Business and Academic Director of the Strategy Research Center, all at Columbia University. Dr. Harrigan is a founding member of the Strategic Management Society. She has taught in several executive development programs for Columbia Business School, for Management Centre Europe (London and Brussels), Frost & Sullivan (London and Frankfurt), and Business Week Executive Programs (Amsterdam and several U.S. cities). She has taught in the Executive MBA Programs of Seoul National University, Ben-Gurion University, St. Gallen University (Switzerland), and University of Cagliari. In 1989, Dr. Harrigan was elected a Fellow of the Academy of Management and has served on its Board of Governors as well as the Advisory Board of Ronin Development Corporation. She has written for and has served on the Board of Editors of various journals including the Strategic Management Journal, Academy of Management Review (Consulting Editor), Academy of Management Journal, Columbia Journal of World Business, Academy of Management Executive, Journal of Business Strategy, and Journal of Engineering and Technology Management.

Leon Hendrix

Mr. Leon J. Hendrix, Jr., is Independent Director of Cambrex Corporation. Mr. Hendrix retired as Chairman of the Governance Committee and Member of the Compensation Committee of the Board. Mr. Hendrix served as Chairman of Remington Arms Co. from December 1997 until his retirement in May 2007. From December 1997 until April 1999 he was also Chief Executive Officer. From 1993 to 2000, Mr. Hendrix was a Principal of Clayton, Dubilier & Rice, Inc., a private investment firm. Prior thereto, Mr. Hendrix was with Reliance Electric Company, a manufacturer and seller of industrial and telecommunications equipment and services. Since 1973, he held a series of executive level positions with Reliance Electric Company, most recently as Chief Operating Officer. Mr. Hendrix was a member of the Board of Directors of Keithley Instruments, Inc. from 1990 to 2010 and NACCO Industries from 1995 to 2006. He is a Member and Past Chairman of the Clemson University Board of Trustees.

Ilan Kaufthal

Mr. Ilan Kaufthal is Independent Director of Cambrex Corporation since 1983. Mr. Kaufthal is currently Member of the Audit and Compensation Committees of the Board. Mr. Kaufthal is currently Chairman of East Wind Advisors, a broker dealer. Mr. Kaufthal currently serves as a member of the Boards of Directors of Tronox, Inc., a publicly traded producer of titanium dioxide pigment based in Stamford, CT, Blyth, Inc., a publicly traded gift and multilevel marketing company based in Greenwich, CT, BioReference Laboratories, Inc., a publicly traded full service clinical diagnostic laboratory in the U.S. providing testing and related services, Quinpario Acquisition Corporation 2, a publicly traded company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, Edmunds.com, a private company and POOF®-Slinky Inc., a private branded childrens’ consumer products business. He was Vice Chairman of Investment Banking at Bear,Stearns & Co. Inc. from May 2000 until June 2008. Prior to joining Bear, Stearns & Co. Inc., Mr. Kaufthal was with Schroder & Co. Incorporated as Vice Chairman and head of mergers and acquisitions for thirteen years. Prior thereto, he was with NL Industries, Inc., a firm in the chemicals and petroleum services businesses, as its Senior Vice President and Chief Financial Officer.

Peter Tombros

Mr. Peter G. Tombros is Independent Director of Cambrex Corporation. Since 2006, Mr. Tombros has been Chairman of the Audit Committee and Member of the Governance Committee of the Board. Since 2006, Mr. Tombros has been Professor, Distinguished Executive in Residence, Eberly College of Science BS/MBA Program, Pennsylvania State University. From 2001 until 2005, he was Chairman of the Board and Chief Executive Officer of VivoQuest, a private biopharmaceutical company. From 1994 to 2001, he served as President and Chief Executive Officer of Enzon Pharmaceuticals. Before joining Enzon Pharmaceuticals, Mr. Tombros spent 25 years with Pfizer, Inc. as Vice President of Marketing, Vice President Corporate Strategic Planning, Senior Vice President and General Manager and as Executive Vice President of Pfizer Pharmaceuticals, Inc. Mr. Tombros is Director and Non-Executive Chairman of the Board of Directors of NPS Pharmaceuticals, a publicly traded company.

Stephanie LaFiura

Options Compensation